# Advisor Review - GPT-5.2

**Role:** Academic advisor checking for fatal errors
**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Timestamp:** 2026-01-31T03:37:25.495898
**Response ID:** resp_084451e6457f76a000697d6a42dfec8190988881b0bed28b1b
**Tokens:** 28995 in / 6189 out
**Response SHA256:** 0f9ad7657a8ceb61

---

I checked the draft strictly for *fatal* problems in (1) data–design alignment, (2) regression sanity, (3) completeness, and (4) internal consistency. I did **not** find any issues that would make the design impossible to execute, the regressions obviously broken, the paper incomplete, or the quantitative claims inconsistent with the presented tables/figures.

## 1) Data–Design Alignment (critical)
- **Treatment timing vs. data coverage:** The study window is **2016–2019** (FARS), and the time-varying retail treatment starts (CO/WA/OR pre-2016; NV **July 2017**; CA **Jan 2018**) are all **within or before** the data window. No cohort requires post-2019 data.
- **Post-treatment observations:** NV and CA have post-treatment observations (2017H2–2019 for NV; 2018–2019 for CA). There are observations on both sides of the border (e.g., Table 2 effective N left/right > 0).
- **Treatment definition consistency:** Throughout, the “legal” definition is consistently framed as **recreational retail sales operational** (not mere legalization). Border regimes by period (Table 13) match that timing.

## 2) Regression Sanity (critical)
I scanned all reported regression tables for impossible values and obviously broken outputs:
- **Table 2 (main RDD):** Coefficients are in plausible ranges for a binary outcome in probability units (≈0.04–0.12). SEs are plausible (≈0.04–0.09). CIs are sensible and within [-1,1]. No anomalies.
- **Table 4 (distance to dispensary):** Coefficients and clustered SEs are small and plausible; R² values are in [0,1]. No “NA/Inf”.
- **Tables 6–11 (heterogeneity / placebo / first-stage / donut / residency):** All coefficients/SEs are within plausible ranges; no absurd magnitudes; no negative SEs; no R² issues; no impossible probability effects.
- **Table 12 (power/MDE):** Arithmetic is consistent with the stated formula (2.80 × SE).

No fatal regression-output red flags (e.g., enormous SEs indicating collinearity artifacts, R² outside [0,1], NA/Inf outputs) appear in the presented tables.

## 3) Completeness (critical)
- All main regression tables reported include **standard errors** and **sample sizes** (effective N where appropriate for RD).
- Figures/tables referenced in the included text appear to exist in the draft excerpt (e.g., Figures 1–9, Tables 1–13). I did not see “TBD/TODO/XXX/NA” placeholders in tables.
- Methods described (main RDD; donut RDD; border decomposition; residency restriction; placebo borders; distance-to-dispensary) have corresponding reported results in the draft.

## 4) Internal Consistency (critical)
Key quantitative claims in the abstract/body match the reported tables:
- Baseline RDD: **0.092 (SE 0.059, p=0.127)** matches Table 2, col (1).
- Single-vehicle in-state: **−0.052 (SE 0.114, p=0.649)** matches Table 11, col (3).
- Donut 2km: **0.237 (SE 0.082)** matches Table 9.
- Border-period definitions are consistent between Section 3.3 and Table 13.

I did not find contradictions like mismatched Ns, swapped signs, or treatment timing that conflicts across sections.

ADVISOR VERDICT: PASS